Stocks and Investing Stocks and Investing
Wed, March 1, 2023

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $144 on, Mar 1st, 2023


Published on 2024-10-28 02:01:07 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $137 to $144 on, Mar 1st, 2023.

Judah has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Judah's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Judah


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $160 on, Tuesday, February 28th, 2023
  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
Contributing Sources